Purpose: To compare the refractive prediction errors (PEs) of formulas included in the ESCRS intraocular lens (IOL) power calculator to aid in informed decisions on IOL power selection based on the output of this tool. Setting: Cullen Eye Institute, Baylor College of Medicine, Houston, Texas. Design: Retrospective case-series. Methods: 748 eyes of 748 patients after implantation of 1 of 3 lenses were included, single-piece: the SN60WF, PCB00/ZCB00 and 3-piece: MA60MA. IOL constants recommended by the calculator were used for the study. We performed analysis for the whole dataset, short (25 mm) as well as in subgroups based on the type of the implanted IOL. SD and root mean square absolute error (RMSAE) were selected as the primary endpoints. Results: Cooke K6 had the lowest SD of PEs in the whole dataset (P < .05) when compared with Barrett, EVO, and Hoffer QST. In the subgroup of long eyes, the Kane formula had the lowest RMSAE (P < .05) when compared with Barrett and EVO. No significant differences in primary endpoints for implantation of the 3 types of IOLs were found. However, the median absolute error after implantation of the MA60MA was significantly higher for Hoffer QST than for all other formulas except for Pearl-DGS. Conclusions: Significant differences in the performance of formulas included in the calculator were found. In the whole dataset, Cooke K6 had the lowest SD of PEs among the analyzed formulas.

Purpose: Animal studies suggest that gut bacteria metabolites are involved in regulation of intraocular pressure or development of glaucoma. However, clinical data are lacking. Here, we wanted to compare level of trimethylamine (TMA), an uremic toxin produced by gut bacteria, along with betaine and trimethylamine N-oxide (TMAO), a substrate and a product of its metabolism, in the aqueous humor and in plasma of patients with glaucoma and their controls. Methods: Twenty patients were selected for cataract phacoemulsification, and 20 patients selected for phacotrabeculectomy were enrolled in the study. Patients were matched with controls on systemic diseases and estimated glomerular filtration rate. Blood samples were collected in the preoperative suite, whereas aqueous humor samples were collected as the first step of both procedures. Subsequently, level of betaine, TMA and TMAO was analyzed by means of chromatography. Results: In the aqueous humor, level of TMA, but not betaine or TMAO, was significantly higher in the phacotrabeculectomy group than in the phacoemulsification group. Plasma level of betaine, TMA and TMAO was similar between groups. In both groups, level of betaine and TMA, but not TMAO, was significantly higher in plasma than in the aqueous humor. Conclusion: TMA, but not TMAO or betaine level, is increased in the aqueous humor of patients with glaucoma. TMA might play a role in pathogenesis of glaucoma; however, prospective studies are needed to confirm our findings.

Sarcoidosis-associated uveitis, is the predominant ocular sarcoidosis presentation, which affects both adults and children. For adults, international ocular sarcoidosis criteria (IWOS) and sarcoidosis-associated uveitis criteria (SUN) are defined. However, for children they are not yet established internationally. Due to the specificity of pediatric manifestations of sarcoidosis, this task is even more challenging. In children, sarcoidosis is subdivided into Blau syndrome and early-onset sarcoidosis (BS/EOS) affecting younger children (< 5 years) and the one affecting older children with clinical presentation resembling adults. Differential diagnosis, clinical work-up as well as diagnostic criteria should be adapted to each age group. In this article, we review the clinical manifestation of sarcoidosis-associated uveitis in adults and children and the sensitivity and specificity of various ocular sarcoidosis diagnostic modalities, including chest X-ray and CT, FDG PET-CT, gallium-67 scintigraphy, bronchoalveolar lavage fluid, genetic testing for NOD2 mutations and serum biomarkers, such as ACE, lysozyme and IL2R.

Glaucoma is an optic nerve neuropathy of undetermined cause. Although many mechanisms are thought to be involved in the development and progression of the disease, only an increased intraocular pressure has been established as a clinically significant modifiable risk factor. Nevertheless, up to 40% of patients develop glaucoma without evidence of increased intraocular pressure.  Ample evidence suggests that alterations in the control of arterial blood might negatively affect optic nerve function. However, evidence-based guidelines on the management of arterial blood pressure in glaucoma patients are lacking.
Regrettably, intraocular pressure is generally not included as a secondary end-point in clinical trials on arterial hypertension. Considering the relative simplicity of intraocular pressure measurements and large number of patients included in hypertension studies, the benefits of including intraocular pressure as a secondary end-point could be of a great value for improving care for glaucoma patients. Therefore, closer collaboration between cardiologists and ophthalmologists is needed.  Glaucoma is an optic nerve neuropathy of undetermined cause. Although many mechanisms are thought to be involved in the development and progression of the disease, only an increased intraocular pressure has been established as a clinically significant modifiable risk factor. Nevertheless, up to 40% of patients develop glaucoma without evidence of increased intraocular pressure.  Ample evidence suggests that alterations in the control of arterial blood might negatively affect optic nerve function. However, evidence-based guidelines on the management of arterial blood pressure in glaucoma patients are lacking.
Regrettably, intraocular pressure is generally not included as a secondary end-point in clinical trials on arterial hypertension. Considering the relative simplicity of intraocular pressure measurements and large number of patients included in hypertension studies, the benefits of including intraocular pressure as a secondary end-point could be of a great value for improving care for glaucoma patients. Therefore, closer collaboration between cardiologists and ophthalmologists is needed. 

Mechanisms controlling intraocular pressure (IOP) and arterial blood pressure (BP) share similar mediators, including gut bacteria metabolites. Here, we investigated the effects of valeric acid (VA), a short chain fatty acid produced by microbiota from undigested carbohydrates, on IOP and BP. To test if gut VA penetrates to the eye we evaluated eyes’ homogenates after the administration of D9-VA into the colon. Additionally, the following experimental series were performed on 16-week-old Sprague Dawley rats to analyze the influence of VA on IOP: vehicle treatment; VA treatment; VA + hydroxybutyrate - a short chain fatty acids’ G protein-coupled receptor 41/43 (GPR 41/43) blocker (ANT); hydroxybutyrate; VA + angiotensin II; angiotensin II; VA treatment in rats with superior cervical ganglion excision and sham operated rats. D9-VA rapidly penetrated from the colon to the eye. VA significantly decreased IOP and BP. The decrease in IOP was gradual and lasted through the experiment. In contrast, a decrease in BP was instantaneous and lasted no longer than 10 min. Angiotensin II, ANT, and sympathetic denervation did not influence the effect of VA on IOP. In conclusion, colon-derived VA penetrates to the eye and decreases IOP. The effect is independent from BP changes, angiotensin II, GPR41/43, and sympathetic eye innervation.